Daniel E Freedberg, Joseph Conigliaro, Timothy C Wang, Kevin J Tracey, Michael V Callahan, Julian A Abrams, Famotidine Research Group PMID: 32446698 PMCID: PMC7242191 DOI: 10.1053/j.gastro.2020.05.053 AbstractNo abstract available. Keywords: Histamine H2 Antagonists, Famotidine Source: https://pubmed.ncbi.nlm.nih.gov/32446698/ Archive: https://archive.is/wip/xU10m

Authors: Malone RW, Tisdall P, Fremont-Smith P, Liu Y, Huang XP, White KM PMID: 32702719 PMCID: PMC7336703 doi: 10.21203/rs.3.rs-30934/v3 Abstract SARS-CoV-2 infection is required for COVID-19, but many signs and symptoms of COVID-19 differ from common acute viral diseases. Currently, there are no pre- or post-exposure prophylactic COVID-19 medical countermeasures. Clinical data suggest that famotidine [...]

Authors: Janowitz T, Baglenz E, Pattinson D, Wang TC, Conigliaro J PMID: 32499303 PMCID: PMC7299656 DOI: 10.1136/gutjnl-2020-321852 Abstract Objective: Treatment options for non-hospitalised patients with coronavirus disease 2019 (COVID-19) to reduce morbidity, mortality and spread of the disease are an urgent global need. The over-the-counter histamine-2 receptor antagonist famotidine is a putative therapy for COVID-19. [...]

Authors: Freedberg DE, Conigliaro J, Sobieszczyk ME, Markowitz DD PMID: 32446698 PMCID: PMC7242191 doi: 10.1053/j.gastro.2020.05.053 Abstract Coronavirus Disease 2019 (COVID-19) caused 2 million cases and more than 150,000 deaths worldwide as of mid-April 2020.1 Clinical trials are under way to assess the efficacy of a variety of antiviral drugs; however, many of these drugs have [...]